Shamburg News · 8-K filed Nov 16, 2026, 7:17 AM EST
Larimar Therapeutics Reports Third Quarter 2026 Results and Completed BLA Submission for Nomlabofusp
LRMR · Larimar Therapeutics, Inc.
- Earnings
- Materiality: high
Larimar Therapeutics reported third quarter 2026 results, including a net loss of $31.1 million, or $0.29 per common share, compared with a net loss of $47.7 million, or $0.61 per share, a year earlier. The company stated it completed its rolling BLA submission seeking accelerated approval of nomlabofusp for Friedreich's ataxia and had $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with cash runway projected into late Q2 2027. No guidance or adjusted EPS was provided in the filing.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-462054.
Written from the filing by Shamburg Markets. Figures are as reported by the company.